Cited by 52Heart Failure Treatment and ManagementHealth disparities and outcomesHeart rate and cardiovascular health

Community Care in England: Reducing Socioeconomic Inequalities in Heart Failure

Open access
Hawkins, Nathaniel M., Scholes, Shaun, Bajekal, Madhavi, Love, Hande, O'Flaherty, Martin, Raine, Rosalind, Capewell, Simon·2012·Circulation

Abstract

BACKGROUND: Socioeconomic deprivation is associated with increased heart failure (HF) incidence, hospitalization rates, and mortality. However, whether the delivery of survival-enhancing medical therapy is equitable remains uncertain. We examined secular trends in the uptake of key medical therapies (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, spironolactone) stratified by socioeconomic circumstances in patients with HF. Secondary analyses examined trends in HF incidence, prevalence, and survival. METHODS AND RESULTS: This study was a cross-sectional observational analysis of nationally representative primary care data from England. Treatments for patients with HF in 1999 and 2007 (n=13 330) were extracted from the General Practice Research Database. Socioeconomic circumstances were defined with the Index of Multiple Deprivation 2007, a weighted composite of 7 area-level deprivation domains. Treatment uptake estimates were age standardized. The incidence and prevalence of HF decreased year to year. Although clear socioeconomic gradients in both the incidence and prevalence of HF were apparent, the absolute difference between most and least deprived reduced over time. Uptake of therapies improved over time in both men and women. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% to 64%, β-blocker uptake from 12% to 41%, and spironolactone uptake from 3% to 20%. Modest age and sex inequalities were apparent. However, no consistent socioeconomic gradients were observed in either treatment or case fatality. CONCLUSIONS: Socioeconomic gradients in the incidence and prevalence of HF are reducing. Treatment is generally equitable and independent of socioeconomic circumstances. Most important, no significant inequality in outcomes was apparent. Future strategies should continue to address inequalities in the underlying causes of HF and to increase overall treatment levels further.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.088047

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hawkins, N. M., Scholes, S., Bajekal, M., Love, H., O'Flaherty, M., Raine, R., & Capewell, S.
Affiliations
  • University of Liverpool (GB)
  • From the Institute of Cardiovascular Medicine and Sciences, Liverpool Heart and Chest Hospital, Liverpool (N.M.H.); Department of Applied Health Research, University College London, London (S.S., M.B., R.R.); Legal and General Assurance Society Ltd, Surrey (H.L.); and Division of Public Health and Policy, University of Liverpool, Liverpool (M.O., S.C.), UK.
Venue
Circulation
Published
2012-08-28
Volume
126
Issue
9
Pages
1050-1057
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2101869743
Cited by
52
References
51
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 7 · 2015: 3 · 2014: 3 · 2013: 7 · 2012: 1
FWCI
2.88
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Circulation (publishedVersion, other-oa)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Social Sciences › Health › Health disparities and outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
heart failure, socioeconomic deprivation, health disparities, treatment uptake, ACE inhibitors, angiotensin receptor blockers, beta-blockers, spironolactone, heart failure incidence, heart failure prevalence, case fatality, secular trends, Index of Multiple Deprivation, primary care
MeSH terms
Adult, Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Agents, Community Health Services, Drug Utilization, England, Female, Health Status Indicators, Heart Failure, Humans, Male, Middle Aged, National Health Programs, Poverty, Socioeconomic Factors, Spironolactone, Incidence, Prevalence, Survival Rate, Healthcare Disparities, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review